Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Novo Nordisk is emphasising that most patients taking CagriSema had mild-to-moderate side effects that were similar to Wegovy, with a more robust effect on weight loss and very low discontinuation ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Novo Nordisk reveals three new weight loss drugs, aiming to offer diverse options for obesity and weight management. ... CagriSema is, as the name hints, semaglutide but more ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose.

CHICAGO — CagriSema, a new weekly injection from Novo Nordisk combining the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide, significantly reduced weight and improved ...

Among participants who were fully adherent to their regimen, mean weight loss was –22.7% in the CagriSema group, and 40.4% of participants assigned CagriSema who were fully adherent lost at ...